Astellas Pharma Inc.
ALPMYOTCHealthcare● Active
$13.49
+$0.26(+1.97%)
Market Cap$24.2B
P/E Ratio—
52W High$17.35
52W Low$9.11
Astellas Pharma Inc. (ALPMY) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ALPMY · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: Apr 27, 2026EPS Actual
$0.33
Est. $0.19 · +70.0%
Revenue
$3.37B
Est. $3.28B · +2.8%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Apr 27, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue🔥 10-Quarter EPS Beat Streak
ALPMY reports quarterly as a OTC-listed Drug Manufacturers - General company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Jul 29, 2026 | $0.31 | — | — | — | $3.52B | — |
| ▲ Q2 FY2026 | Apr 27, 2026 | $0.19 | $0.33 | +70.0% | $3.37B | $3.28B | +2.8% |
| ▲ Q1 FY2026 | Feb 4, 2026 | $0.29 | $0.36 | +24.8% | $3.64B | $3.38B | +7.6% |
| ▲ Q4 FY2025 | Oct 30, 2025 | $0.20 | $0.30 | +50.5% | $3.56B | $3.42B | +3.9% |
| ▲ Q3 FY2025 | Jul 30, 2025 | $0.14 | $0.40 | +195.0% | $3.49B | $3.24B | +8.0% |
| ▲ Q2 FY2025 | Apr 25, 2025 | $0.15 | $0.27 | +84.3% | $3.16B | $3.16B | -0.1% |
| ▲ Q1 FY2025 | Feb 4, 2025 | $0.16 | $0.30 | +89.9% | $3.29B | $2.91B | +13.1% |
| ▲ Q4 FY2024 | Oct 30, 2024 | $0.12 | $0.13 | +7.5% | $3.11B | $2.96B | +5.1% |
Q3 FY2026
Jul 29, 2026
EPS Actual
—
EPS Est.
$0.31
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 27, 2026Beat
EPS Actual
$0.33
EPS Est.
$0.19
EPS Surpr.
+70.0%
Revenue
$3.37B
Q1 FY2026
Feb 4, 2026Beat
EPS Actual
$0.36
EPS Est.
$0.29
EPS Surpr.
+24.8%
Revenue
$3.64B
Q4 FY2025
Oct 30, 2025Beat
EPS Actual
$0.30
EPS Est.
$0.20
EPS Surpr.
+50.5%
Revenue
$3.56B
Q3 FY2025
Jul 30, 2025Beat
EPS Actual
$0.40
EPS Est.
$0.14
EPS Surpr.
+195.0%
Revenue
$3.49B
Q2 FY2025
Apr 25, 2025Beat
EPS Actual
$0.27
EPS Est.
$0.15
EPS Surpr.
+84.3%
Revenue
$3.16B
Q1 FY2025
Feb 4, 2025Beat
EPS Actual
$0.30
EPS Est.
$0.16
EPS Surpr.
+89.9%
Revenue
$3.29B
Q4 FY2024
Oct 30, 2024Beat
EPS Actual
$0.13
EPS Est.
$0.12
EPS Surpr.
+7.5%
Revenue
$3.11B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2027 | $22.20 | $22.74 | $23.44 | 1 |
| Q4 FY2026 | $56.42 | $57.79 | $59.57 | 1 |
| Q3 FY2026 | $51.65 | $52.90 | $54.54 | 1 |
| Q2 FY2026 | $49.08 | $50.28 | $51.83 | 1 |
| Q1 FY2026 | $30.27 | $31.01 | $31.97 | 1 |
| Q4 FY2025 | $44.66 | $45.75 | $47.16 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2027 | $534B | $544B | $556B | 1 |
| Q4 FY2026 | $602B | $613B | $628B | 1 |
| Q3 FY2026 | $569B | $579B | $593B | 2 |
| Q2 FY2026 | $553B | $563B | $576B | 2 |
| Q1 FY2026 | $514B | $523B | $536B | 3 |
| Q4 FY2025 | $484B | $531B | $560B | 6 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | Apr 27, 2026 | +70.0% | $15.43 | $15.05 | -2.46% |
| ▲ Q1 FY2026 | Feb 4, 2026 | +24.8% | $14.11 | $15.35 | +8.79% |
| ▲ Q4 FY2025 | Oct 30, 2025 | +50.5% | $10.28 | $10.90 | +6.03% |
| ▲ Q3 FY2025 | Jul 30, 2025 | +195.0% | $10.07 | $10.35 | +2.78% |
| ▲ Q2 FY2025 | Apr 25, 2025 | +84.3% | $9.57 | $10.07 | +5.22% |
| ▲ Q1 FY2025 | Feb 4, 2025 | +89.9% | $9.52 | $9.15 | -3.89% |
| ▲ Q4 FY2024 | Oct 30, 2024 | +7.5% | $11.64 | $12.30 | +5.67% |
| ▲ Q3 FY2024 | Aug 1, 2024 | +300.0% | $11.61 | $12.30 | +5.94% |
Q2 FY2026-2.46%
Report Date
Apr 27, 2026
EPS Beat/Miss
+70.0%
Price Before
$15.43
Price After
$15.05
Q1 FY2026+8.79%
Report Date
Feb 4, 2026
EPS Beat/Miss
+24.8%
Price Before
$14.11
Price After
$15.35
Q4 FY2025+6.03%
Report Date
Oct 30, 2025
EPS Beat/Miss
+50.5%
Price Before
$10.28
Price After
$10.90
Q3 FY2025+2.78%
Report Date
Jul 30, 2025
EPS Beat/Miss
+195.0%
Price Before
$10.07
Price After
$10.35
Q2 FY2025+5.22%
Report Date
Apr 25, 2025
EPS Beat/Miss
+84.3%
Price Before
$9.57
Price After
$10.07
Q1 FY2025-3.89%
Report Date
Feb 4, 2025
EPS Beat/Miss
+89.9%
Price Before
$9.52
Price After
$9.15
Q4 FY2024+5.67%
Report Date
Oct 30, 2024
EPS Beat/Miss
+7.5%
Price Before
$11.64
Price After
$12.30
Q3 FY2024+5.94%
Report Date
Aug 1, 2024
EPS Beat/Miss
+300.0%
Price Before
$11.61
Price After
$12.30
Avg Beat Reaction+3.51%
Beat Rate8 / 8 quarters
Largest Move+8.79% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ALPMY ends December
Astellas Pharma Inc. (ALPMY) most recently reported earnings on April 27, 2026 for Q2 FY2026, posting EPS of $0.33 — beating the analyst consensus of $0.19 by +70.0%. ALPMY has beaten EPS estimates for 10 consecutive quarters. The next ALPMY earnings date is expected around September 1, 2026.
Each quarter, investors track ALPMY earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ALPMY revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ALPMY's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ALPMY earnings · 5 questionsAstellas Pharma Inc.'s next earnings report is expected around September 1, 2026. ALPMY typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ALPMY historically reports after market close (AMC).
ALPMY earnings datewhen is ALPMY earningsALPMY next earnings datewhen does ALPMY report earningsALPMY earnings calendar
▸ Source: FMP · Astellas Pharma Inc. SEC filings · US GAAP · Astellas Pharma Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026